newsfilter
← Latest News
Business Wire·

ACE-Breast-02 Pivotal Phase 3 Study of Ambrx's ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results

Interim analysis of the ACE-Breast-02 study being conducted by Ambrx's partner, NovoCodex Biopharmaceuticals, was completed by the Independent Data Monitoring Committee (IDMC) The pivotal Phase 3 ACE-Breast-02 study